Global Basal Cell Carcinoma Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 93

Report ID: 1815

Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening by metastasis only in extremely rare cases. According to the American Cancer Society, BCCs constitute around 80% of all non-melanoma skin cancers. Australia has been found to have the highest rate of basal cell carcinoma across the globe. Exposure to ultraviolet radiation is considered as the major cause behind BCC. Use of immunosuppressant drugs further enhance the chances of BCC as the immune system is compromised. White people are more vulnerable to BCC comparatively, according to a research published in the British Medical Journal. The symptoms of BCCs include waxy papules (slightly transparent bump) with pearly appearance and central depression and bleeding from the papules.
The increase in geriatric population, giving rise to numerous skin diseases, such as actinic keratosis and other non-melanoma skin malignancies, is another important factor that has been fueling the demand for basal cell carcinoma treatment substantially. In addition to these, the market is expected to gain considerably from the changing lifestyle of people in developing economies over the coming years as it is anticipated to drive demand for better disease treatments, which in turn, is likely to provide lucrative opportunities for the companies operating in the global basal cell carcinoma treatment market. 
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are considered as the prominent geographical segments of this market. North America, which is the current market leader, is expected to remain dominant over the next few years. The presence of a well-established medical and healthcare infrastructure, increasing expenditure on healthcare, and the high prevalence of basal cell carcinoma in this region are likely to boost the growth of the market for basal cell carcinoma treatment in North America.
In 2018, the global Basal Cell Carcinoma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Basal Cell Carcinoma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Basal Cell Carcinoma Therapeutics development in United States, Europe and China.

The key players covered in this study
Sun Pharmaceuticals
Valeant Pharmaceuticals International
Mylan
F. Hoffmann-La Roche
Merck
...

Market segment by Type, the product can be split into
Surgery
Radiation Therapy
Photodynamic Therapy
Drugs

Market segment by Application, split into
Retail Pharmacies
Hospitals Pharmacies
Cancer Research Institutes

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Basal Cell Carcinoma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Basal Cell Carcinoma Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Basal Cell Carcinoma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Basal Cell Carcinoma Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Surgery
1.4.3 Radiation Therapy
1.4.4 Photodynamic Therapy
1.4.5 Drugs
1.5 Market by Application
1.5.1 Global Basal Cell Carcinoma Therapeutics Market Share by Application (2014-2025)
1.5.2 Retail Pharmacies
1.5.3 Hospitals Pharmacies
1.5.4 Cancer Research Institutes
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Basal Cell Carcinoma Therapeutics Market Size
2.2 Basal Cell Carcinoma Therapeutics Growth Trends by Regions
2.2.1 Basal Cell Carcinoma Therapeutics Market Size by Regions (2014-2025)
2.2.2 Basal Cell Carcinoma Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Basal Cell Carcinoma Therapeutics Market Size by Manufacturers
3.1.1 Global Basal Cell Carcinoma Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Basal Cell Carcinoma Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Basal Cell Carcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Basal Cell Carcinoma Therapeutics Key Players Head office and Area Served
3.3 Key Players Basal Cell Carcinoma Therapeutics Product/Solution/Service
3.4 Date of Enter into Basal Cell Carcinoma Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Basal Cell Carcinoma Therapeutics Market Size by Type (2014-2019)
4.2 Global Basal Cell Carcinoma Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
5.2 Basal Cell Carcinoma Therapeutics Key Players in United States
5.3 United States Basal Cell Carcinoma Therapeutics Market Size by Type
5.4 United States Basal Cell Carcinoma Therapeutics Market Size by Application

6 Europe
6.1 Europe Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
6.2 Basal Cell Carcinoma Therapeutics Key Players in Europe
6.3 Europe Basal Cell Carcinoma Therapeutics Market Size by Type
6.4 Europe Basal Cell Carcinoma Therapeutics Market Size by Application

7 China
7.1 China Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
7.2 Basal Cell Carcinoma Therapeutics Key Players in China
7.3 China Basal Cell Carcinoma Therapeutics Market Size by Type
7.4 China Basal Cell Carcinoma Therapeutics Market Size by Application

8 Japan
8.1 Japan Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
8.2 Basal Cell Carcinoma Therapeutics Key Players in Japan
8.3 Japan Basal Cell Carcinoma Therapeutics Market Size by Type
8.4 Japan Basal Cell Carcinoma Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
9.2 Basal Cell Carcinoma Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Basal Cell Carcinoma Therapeutics Market Size by Type
9.4 Southeast Asia Basal Cell Carcinoma Therapeutics Market Size by Application

10 India
10.1 India Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
10.2 Basal Cell Carcinoma Therapeutics Key Players in India
10.3 India Basal Cell Carcinoma Therapeutics Market Size by Type
10.4 India Basal Cell Carcinoma Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Basal Cell Carcinoma Therapeutics Market Size (2014-2019)
11.2 Basal Cell Carcinoma Therapeutics Key Players in Central & South America
11.3 Central & South America Basal Cell Carcinoma Therapeutics Market Size by Type
11.4 Central & South America Basal Cell Carcinoma Therapeutics Market Size by Application

12 International Players Profiles
12.1 Sun Pharmaceuticals
12.1.1 Sun Pharmaceuticals Company Details
12.1.2 Company Description and Business Overview
12.1.3 Basal Cell Carcinoma Therapeutics Introduction
12.1.4 Sun Pharmaceuticals Revenue in Basal Cell Carcinoma Therapeutics Business (2014-2019)
12.1.5 Sun Pharmaceuticals Recent Development
12.2 Valeant Pharmaceuticals International
12.2.1 Valeant Pharmaceuticals International Company Details
12.2.2 Company Description and Business Overview
12.2.3 Basal Cell Carcinoma Therapeutics Introduction
12.2.4 Valeant Pharmaceuticals International Revenue in Basal Cell Carcinoma Therapeutics Business (2014-2019)
12.2.5 Valeant Pharmaceuticals International Recent Development
12.3 Mylan
12.3.1 Mylan Company Details
12.3.2 Company Description and Business Overview
12.3.3 Basal Cell Carcinoma Therapeutics Introduction
12.3.4 Mylan Revenue in Basal Cell Carcinoma Therapeutics Business (2014-2019)
12.3.5 Mylan Recent Development
12.4 F. Hoffmann-La Roche
12.4.1 F. Hoffmann-La Roche Company Details
12.4.2 Company Description and Business Overview
12.4.3 Basal Cell Carcinoma Therapeutics Introduction
12.4.4 F. Hoffmann-La Roche Revenue in Basal Cell Carcinoma Therapeutics Business (2014-2019)
12.4.5 F. Hoffmann-La Roche Recent Development
12.5 Merck
12.5.1 Merck Company Details
12.5.2 Company Description and Business Overview
12.5.3 Basal Cell Carcinoma Therapeutics Introduction
12.5.4 Merck Revenue in Basal Cell Carcinoma Therapeutics Business (2014-2019)
12.5.5 Merck Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details